These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 19476653)
1. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. Turashvili G; Leung S; Turbin D; Montgomery K; Gilks B; West R; Carrier M; Huntsman D; Aparicio S BMC Cancer; 2009 May; 9():165. PubMed ID: 19476653 [TBL] [Abstract][Full Text] [Related]
2. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197 [TBL] [Abstract][Full Text] [Related]
3. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Turbin DA; Leung S; Cheang MC; Kennecke HA; Montgomery KD; McKinney S; Treaba DO; Boyd N; Goldstein LC; Badve S; Gown AM; van de Rijn M; Nielsen TO; Gilks CB; Huntsman DG Breast Cancer Res Treat; 2008 Aug; 110(3):417-26. PubMed ID: 17912629 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847 [TBL] [Abstract][Full Text] [Related]
5. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992 [TBL] [Abstract][Full Text] [Related]
6. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Minot DM; Voss J; Rademacher S; Lwin T; Orsulak J; Caron B; Ketterling R; Nassar A; Chen B; Clayton A Am J Clin Pathol; 2012 Feb; 137(2):270-6. PubMed ID: 22261453 [TBL] [Abstract][Full Text] [Related]
7. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study. van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265 [TBL] [Abstract][Full Text] [Related]
9. Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice. Liao CC; Bakoglu N; Cesmecioglu E; Hanna M; Pareja F; Wen HY; D'Alfonso TM; Brogi E; Yagi Y; Ross DS Pathol Oncol Res; 2024; 30():1611826. PubMed ID: 39267995 [No Abstract] [Full Text] [Related]
10. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337 [TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study. Farshid G; Armes J; Dessauvagie B; Gilhotra A; Kumar B; Mahajan H; Millar E; Pathmanathan N; Snell C Mod Pathol; 2024 Aug; 37(8):100535. PubMed ID: 38852812 [TBL] [Abstract][Full Text] [Related]
12. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry. Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985 [TBL] [Abstract][Full Text] [Related]
13. Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy. Micsik T; Kiszler G; Szabó D; Krecsák L; Hegedűs C; Tibor K; Molnár B Pathol Oncol Res; 2015 Sep; 21(4):1005-11. PubMed ID: 25788005 [TBL] [Abstract][Full Text] [Related]
14. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Mohammed ZM; Going JJ; McMillan DC; Orange C; Mallon E; Doughty JC; Edwards J Histopathology; 2012 Oct; 61(4):675-84. PubMed ID: 22747525 [TBL] [Abstract][Full Text] [Related]
15. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study. Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064 [TBL] [Abstract][Full Text] [Related]
16. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting. Green IF; Zynger DL Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217 [TBL] [Abstract][Full Text] [Related]
17. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers. Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890 [TBL] [Abstract][Full Text] [Related]
18. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)]. Akhdar A; Bronsard M; Lemieux R; Geha S Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120 [TBL] [Abstract][Full Text] [Related]
19. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315 [TBL] [Abstract][Full Text] [Related]
20. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms. Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]